Sino Biopharmaceutical Limited (SBHMY)
For informational purposes only. Not financial advice. Analysis by Sedat Aydin, Founder & Editor-in-Chief | AI-powered analysis. Data sourced from SEC filings and institutional-grade financial providers. Editorially reviewed. Not financial advice.
Sino Biopharmaceutical Limited (SBHMY) with AI Score 54/100 (Hold). Sino Biopharmaceutical Limited is a research and development pharmaceutical conglomerate based in China. Market cap: 0, Sector: Healthcare.
Last analyzed: Mar 16, 2026Sino Biopharmaceutical Limited (SBHMY) Healthcare & Pipeline Overview
Sino Biopharmaceutical Limited is a Chinese pharmaceutical company focused on research, development, and manufacturing of modern Chinese and chemical medicines, including treatments for oncology, cardiovascular diseases, and hepatitis, with a strong presence in the Chinese market and a growing portfolio of innovative drugs.
Investment Thesis
Sino Biopharmaceutical Limited presents an investment opportunity driven by its strong presence in the Chinese pharmaceutical market and its diversified product portfolio. The company's focus on research and development, evidenced by its pipeline of innovative drugs, positions it for sustained growth. With a profit margin of 12.7% and a gross margin of 81.8%, the company demonstrates financial stability. Key catalysts include the continued expansion of its oncology and cardio-cerebral vascular medicine offerings. Potential risks include regulatory changes in the Chinese pharmaceutical market and competition from both domestic and international players. The company's P/E ratio of 24.40 reflects investor expectations of future growth. The dividend yield of 1.51% provides a modest return while investors await capital appreciation.
Based on FMP financials and quantitative analysis
Key Highlights
- Market capitalization of $14.21 billion, reflecting its significant presence in the pharmaceutical industry.
- Profit margin of 12.7%, indicating efficient operations and profitability.
- Gross margin of 81.8%, showcasing strong pricing power and cost management.
- Dividend yield of 1.51%, providing a steady income stream for investors.
- Beta of 0.78, suggesting lower volatility compared to the overall market.
Competitors & Peers
Strengths
- Diversified product portfolio across multiple therapeutic areas.
- Strong research and development capabilities.
- Established distribution network in China.
- Experienced management team.
Weaknesses
- Reliance on the Chinese market.
- Exposure to regulatory changes in China.
- Competition from both domestic and international players.
- Potential for product recalls or safety issues.
Catalysts
- Ongoing: Continued expansion of the oncology product line, driven by increasing cancer incidence in China.
- Ongoing: Development and commercialization of new cardio-cerebral vascular medicines to address the growing prevalence of cardiovascular diseases.
- Upcoming: Potential regulatory approvals for new drug candidates in the pipeline.
- Ongoing: Strategic partnerships and collaborations to expand market reach and access new technologies.
- Ongoing: Increasing healthcare spending and access to healthcare services in China.
Risks
- Potential: Regulatory changes in the Chinese pharmaceutical market, impacting pricing and market access.
- Ongoing: Competition from both domestic and international pharmaceutical companies.
- Potential: Intellectual property infringement and patent disputes.
- Potential: Product recalls or safety issues.
- Ongoing: Currency risk associated with the ADR structure.
Growth Opportunities
- Expansion of Oncology Product Portfolio: Sino Biopharmaceutical has a significant opportunity to expand its oncology product portfolio, addressing the growing demand for cancer treatments in China. The Chinese oncology market is projected to reach substantial value by 2030, driven by increasing cancer incidence and improved diagnosis rates. By investing in research and development of new oncology drugs and expanding its existing product line, Sino Biopharmaceutical can capture a larger share of this market. Timeline: Ongoing, with continuous research and development efforts.
- Development of Cardio-Cerebral Vascular Medicines: With the increasing prevalence of cardiovascular diseases in China, Sino Biopharmaceutical can capitalize on the growing demand for cardio-cerebral vascular medicines. The market for these medicines is expected to grow significantly over the next decade. Sino Biopharmaceutical can leverage its existing product line and invest in the development of new and innovative treatments to address this market opportunity. Timeline: Ongoing, with continuous research and development efforts.
- Penetration of Hepatitis Medicines Market: Sino Biopharmaceutical has a strong presence in the hepatitis medicines market with products like Tianqingganmei injections and Tianqingganping enteric capsules. The company can further penetrate this market by developing new and improved treatments for hepatitis and expanding its distribution network. The hepatitis medicines market in China is expected to grow, driven by increasing awareness and diagnosis rates. Timeline: Ongoing, with continuous research and development efforts.
- Strategic Partnerships and Acquisitions: Sino Biopharmaceutical can pursue strategic partnerships and acquisitions to expand its product portfolio and market reach. By partnering with other pharmaceutical companies and research institutions, Sino Biopharmaceutical can gain access to new technologies and drug candidates. Acquisitions can provide the company with access to new markets and distribution channels. Timeline: Ongoing, with continuous evaluation of potential partnership and acquisition opportunities.
- Expansion into International Markets: While primarily focused on the Chinese market, Sino Biopharmaceutical can explore opportunities to expand into international markets. By registering its products in other countries and establishing distribution networks, Sino Biopharmaceutical can diversify its revenue streams and reduce its reliance on the Chinese market. This expansion could target emerging markets with similar healthcare needs and regulatory environments. Timeline: Medium-term, with gradual expansion into select international markets.
Opportunities
- Expansion into new therapeutic areas.
- Strategic partnerships and acquisitions.
- Expansion into international markets.
- Development of innovative and biosimilar drugs.
Threats
- Pricing pressures from government regulations.
- Competition from generic drug manufacturers.
- Changes in healthcare policies.
- Intellectual property infringement.
Competitive Advantages
- Strong research and development capabilities.
- Diversified product portfolio.
- Established distribution network in China.
- Brand recognition and reputation.
- Proprietary formulations and patents.
About SBHMY
Sino Biopharmaceutical Limited, incorporated in 2000 and headquartered in Wan Chai, Hong Kong, operates as an investment holding company with a focus on research and development in the pharmaceutical sector within the People's Republic of China. The company's operations are structured into three primary segments: Modernised Chinese Medicines and Chemical Medicines, Investment, and Others. Its diverse product portfolio includes treatments for a wide array of conditions, such as oncology (Qingkeshu tablets, Anxian capsules), cardio-cerebral vascular diseases (Kaina and Anrixin tablets), hepatitis (Tianqingganmei injections and Tianqingganping enteric capsules), and orthopedic ailments (Gaisanchun capsules, Yigu injections). In addition to these core products, Sino Biopharmaceutical offers medicines for respiratory system diseases and parenteral nutritious medicines like Xinhaineng and Fenghaina injections. The company also provides a range of other medicines, including Tuotuo tablets and Debaian cataplasms. Beyond pharmaceuticals, Sino Biopharmaceutical is involved in property holdings, pharmaceutical retail and distribution, optometry services, hospital operations, medical management and health information consultancy, bio-tech transfer and consultation, health food manufacturing and sales, and orthopedic outpatient and surgical procedures. The company continues to expand its research and development efforts to introduce new and innovative pharmaceutical products to the market.
What They Do
- Develops and manufactures modern Chinese medicines and chemical medicines.
- Offers oncology medicines, including tablets and capsules.
- Provides cardio-cerebral vascular medicines.
- Produces hepatitis medicines.
- Manufactures orthopedic medicines.
- Offers respiratory system medicines.
- Provides parenteral nutritious medicines.
- Engages in investment activities.
Business Model
- Develops and manufactures a wide range of pharmaceutical products.
- Sells pharmaceutical products through its distribution network.
- Generates revenue from the sale of medicines for various therapeutic areas.
- Invests in research and development to create new and innovative products.
Industry Context
Sino Biopharmaceutical operates within the rapidly growing Chinese pharmaceutical market. The industry is characterized by increasing demand for healthcare products and services, driven by an aging population and rising income levels. The Chinese government's healthcare reforms and increasing regulatory scrutiny are shaping the competitive landscape. Sino Biopharmaceutical competes with both domestic and international pharmaceutical companies, focusing on innovative drug development and strategic partnerships to maintain its market position. The biotechnology sector is experiencing significant growth, fueled by advancements in research and development and increasing investment in innovative therapies.
Key Customers
- Hospitals and healthcare institutions.
- Pharmacies and drug stores.
- Patients requiring pharmaceutical treatments.
- Healthcare professionals prescribing medications.
Financials
Chart & Info
Sino Biopharmaceutical Limited (SBHMY) stock price: Price data unavailable
Latest News
-
Sanofi bets on Sino Biopharm’s transplant drug in $1.5bn licensing deal
Yahoo! Finance: SBHMY News · Mar 4, 2026
-
Stocks That Hit 52-Week Highs On Friday
· Jan 17, 2020
Analyst Consensus
Consensus Rating
Aggregated Buy/Hold/Sell recommendations from Benzinga, Yahoo Finance, and Finnhub for SBHMY.
Price Targets
Wall Street price target analysis for SBHMY.
MoonshotScore
What does this score mean?
The MoonshotScore rates SBHMY's growth potential on a scale of 0-100 across multiple factors including innovation, market disruption, financial health, and momentum.
Leadership: S. Y. Tse
CEO
S. Y. Tse serves as the CEO of Sino Biopharmaceutical Limited, leading a workforce of over 24,000 employees. Information regarding S. Y. Tse's detailed career history, education, and previous roles is not available in the provided data. However, as the CEO, S. Y. Tse is responsible for the overall strategic direction and operational performance of the company.
Track Record: Information regarding S. Y. Tse's specific achievements, strategic decisions, and company milestones under their leadership is not available in the provided data. However, as the CEO of Sino Biopharmaceutical Limited, S. Y. Tse plays a critical role in driving the company's growth and success.
Sino Biopharmaceutical Limited ADR Information Unsponsored
An American Depositary Receipt (ADR) is a certificate representing shares of a foreign company trading on U.S. stock exchanges. SBHMY, as an ADR, allows U.S. investors to invest in Sino Biopharmaceutical Limited without the complexities of cross-border transactions. The ADR represents a specific number of Sino Biopharmaceutical's shares held by a depositary bank.
- Home Market Ticker: Hong Kong Stock Exchange (SBHM), Hong Kong
- ADR Level: 1
- ADR Ratio: 1:1
- Home Market Ticker: SBHM
SBHMY OTC Market Information
The OTC Other tier represents the lowest tier of the over-the-counter (OTC) market. Companies trading on this tier often have limited reporting requirements and may not meet the listing standards of major exchanges like the NYSE or NASDAQ. This can result in less transparency and increased risk for investors compared to companies listed on regulated exchanges. OTC Other stocks often have minimal trading volume and liquidity.
- OTC Tier: OTC Other
- Disclosure Status: Unknown
- Limited financial disclosure and transparency.
- Potential for fraud or manipulation.
- Lack of regulatory oversight.
- Illiquidity and price volatility.
- Higher risk of delisting or going out of business.
- Verify the company's registration and legal status.
- Review available financial statements and disclosures.
- Assess the company's business model and competitive landscape.
- Evaluate the management team and their track record.
- Understand the risks associated with investing in OTC stocks.
- Consult with a financial advisor.
- Check for any regulatory actions or legal proceedings.
- Established business operations and product portfolio.
- Presence in the pharmaceutical industry.
- ADR listing, indicating some level of compliance.
- Employee count of 24379, suggesting a significant operation.
- Headquarters in Hong Kong, a major financial center.
What Investors Ask About Sino Biopharmaceutical Limited (SBHMY)
What does Sino Biopharmaceutical Limited do?
Sino Biopharmaceutical Limited is a research and development-driven pharmaceutical company that develops, manufactures, and markets a wide range of pharmaceutical products. Its portfolio includes medicines for oncology, cardio-cerebral vascular diseases, hepatitis, orthopedics, and respiratory system ailments. The company operates primarily in China and focuses on both modern Chinese medicines and chemical medicines, catering to the growing healthcare needs of the Chinese population. It also holds properties, retails pharmaceutical products, and offers health-related services.
What do analysts say about SBHMY stock?
AI analysis is currently pending for SBHMY. Generally, analysts evaluate pharmaceutical companies based on their product pipeline, regulatory approvals, market share, and financial performance. Key valuation metrics include price-to-earnings ratio, price-to-sales ratio, and discounted cash flow analysis. Growth considerations often focus on the company's ability to develop and commercialize new drugs, expand into new markets, and maintain its competitive position. The pending AI analysis will provide further insights.
What are the main risks for SBHMY?
Sino Biopharmaceutical faces several risks, including regulatory changes in the Chinese pharmaceutical market, which can impact pricing and market access. Competition from both domestic and international players poses a threat to market share. Intellectual property infringement and patent disputes can also negatively affect the company's profitability. Additionally, product recalls or safety issues can damage the company's reputation and lead to financial losses. As an ADR, SBHMY is also subject to currency risk.
What are the key factors to evaluate for SBHMY?
Sino Biopharmaceutical Limited (SBHMY) currently holds an AI score of 54/100, indicating moderate score. Key strength: Diversified product portfolio across multiple therapeutic areas.. Primary risk to monitor: Potential: Regulatory changes in the Chinese pharmaceutical market, impacting pricing and market access.. This is not financial advice.
How frequently does SBHMY data refresh on this page?
SBHMY prices update in real time during U.S. market hours (9:30 AM-4:00 PM ET, weekdays). Fundamentals refresh after quarterly or annual filings. Analyst ratings and AI insights update daily. News is aggregated continuously from financial sources.
What has driven SBHMY's recent stock price performance?
Recent price movement in Sino Biopharmaceutical Limited (SBHMY) can be influenced by earnings results, analyst revisions, sector rotation, and broader market sentiment. Notable catalyst: Diversified product portfolio across multiple therapeutic areas.. Check the News and Technical Analysis tabs for the latest drivers. Past performance does not predict future results.
Should investors consider SBHMY overvalued or undervalued right now?
Determining whether Sino Biopharmaceutical Limited (SBHMY) is overvalued or undervalued requires examining multiple metrics. Compare valuation ratios (P/E, P/S, EV/EBITDA) against sector peers for a comprehensive view.
What research should beginners do before buying SBHMY?
Before investing in Sino Biopharmaceutical Limited (SBHMY), research these four areas: (1) the company's revenue model and competitive position (see Company Overview), (2) financial health through revenue growth, margins, and cash flow (see MoonshotScore), (3) what Wall Street analysts recommend and their price targets (see Analyst tab), and (4) specific risk factors that could impact the stock (see Risk Factors section).
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
Data provided for informational purposes only.
- Information is based on available data and may be subject to change.
- AI analysis is pending and will provide further insights.